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In this issue of Structure, Melero and colleagues use electron microscopy combined with biochemistry to
provide structural insight into the complex between SMG1, SMG8, SMG9, UPF1, and UPF2, elucidating
how key players in nonsense-mediated mRNA decay assemble at the initial steps of the process.Nonsense-mediated mRNA decay (NMD)
is a translation-dependent surveillance
mechanism that degrades transcripts
with a premature termination codon
(PTC), preventing the accumulation of
truncated proteins in the cell. NMD acts
to degrade mRNAs with mutations intro-
duced either at the DNA level or in the
RNA itself during transcription or process-
ing. Because about a third of all disease
mutations in humans yield mRNAs with a
PTC, NMD is also a clinically relevant
pathway (Schweingruber et al., 2013).
Furthermore, NMD has been shown to
affect gene expression by regulating the
abundance of physiological transcripts
that, for example, acquire an apparent
PTC through alternative splicing mecha-
nisms or inclusion of upstream ORFs
(Schweingruber et al., 2013). Triggering
NMD requires the formation of a series of
protein complexes that recognize the
PTC and subsequently recruit the degra-
dation machinery. In humans, PTCs are
often recognized by their position relative
to the exon junction complex (EJC) (Le
Hir et al., 2001).
The core NMD factors are UPF proteins
(UPF1, UPF2, and UPF3) that interact
to sequentially assemble a ‘‘surveillance
complex’’ (Serin et al., 2001; Chamieh
et al., 2008). UPF1, a conserved ATP-
dependent RNA helicase, interacts
directly with the release factors eRF1
and eRF2 on the ribosome together with
SMG1 forming the so-called SURF com-
plex that links NMD to active translation
(Kashima et al., 2006). A key event during
the initial steps of NMD is the phosphory-
lation of UPF1 by the SMG1 kinase (Cha-
mieh et al., 2008), which is in turn regu-
lated by UPF2 and UPF3.
SMG1 is a large (3,657 amino acid)
phosphatidylinositol 3-kinase-related ki-
nase, consisting of a globular C-terminal
region with the catalytic site and an elon-1074 Structure 22, August 5, 2014 ª2014 Elsgated N-terminal region of a-helical HEAT
repeats. SMG1 activity is finely regulated
by several interactions, not only with the
NMD factors UPF2 and UPF3, but also
with the kinase inhibitors SMG8 and
SMG9 (Yamashita et al., 2009; Arias-Pal-
omo et al., 2011).
At present, structural information is
available that provides detailed mecha-
nistic insight on EJC binding to RNA,
on the interaction that assembles the
UPF complex on the EJC and on UPF1
function in NMD (Schweingruber et al.,
2013; Llorca, 2013). However, given that
NMD is tightly regulated with numerous
dynamic interactions and remodeling
of complexes, several open questions
remain. In particular, we still have limited
mechanistic information on the link be-
tween PTC recognition by the ribosome
and the steps leading to the recruitment
of UPF1 to NMD substrates and to UPF1
phosphorylation. A mechanistic under-
standing of this process requires the com-
bination of structural studies providing
static snapshots, with biochemical and
functional assays. The article by Melero
et al. (2014) in this issue of Structure is a
beautiful example of how such a combi-
nation can provide insights into the dy-
namics of a multiprotein complex.
Melero et al. (2014) present structural
information for a series of complexes
formed by SMG1, SMG8, SMG9, UPF1,
and UPF2 that gives insight into confor-
mational changes and remodeling steps
that might occur during NMD in vivo.
SMG1 is a core scaffolding component
of NMD complexes, but how it organizes
the other components was previously
not appreciated. The current view is that
UPF2 binds to SMG1 via UPF1. Now Me-
lero et al. (2014) present evidence that
UPF1 and UPF2 can associate indepen-
dently and simultaneously to the kinase.
Mutant forms of UPF1 and UPF2 unableevier Ltd All rights reservedto interact with each other are still able
to bind to SMG1, changing our under-
standing of the recruitment of UPF pro-
teins to the kinase. Melero et al. (2014)
used electron microscopy (EM) of nega-
tively stained samples and were able to
obtain low-resolution EM surfaces for
five different structures, including SMG1
and four subcomplexes of SMG1 with
UPF1, UPF2, SMG8, and SMG9. They
combined EM with biochemical assays,
revealing complex interactions and also
temporal and spatial constrains in the as-
sembly of the complex.
The work also presents further details
about the inhibition of SMG1 by SMG8/
9. The EM structures also reveal a large
conformational change of the HEAT-
repeat region upon SMG8 and SMG9
binding, complementing previous work
by the authors (Arias-Palomo et al.,
2011) (Figure 1). Moreover, they show
that although UPF2 and UPF1 alone
dock at distinct sites on the SMG1 sur-
face, the order of the interactions is
important to assemble a stable complex
with all components and influences the
final conformation of the assembled
pentameric complex. In the pentameric
complex, UPF2 does not contact SMG1
directly, but via UPF1 that appears to
be in an open, uninhibited conformation
(Figure 1). This complex may form when
a preassembled UPF1-UPF2 complex
binds to the SMG1C (SMG1-SMG8-
SMG9) assembly. Indeed, in vitro compe-
tition experiments showed that the
order of interactions is important for sta-
bility. UPF1 can associate when UPF2
is already bound to SMG1C, whereas
UPF2 joining displaces a prebound
UPF1 (Figure 1). This is supported by the
observation that a UPF2 mutant, impaired
in UPF1 binding, no longer displaces pre-
bound UPF1, nor can it associate with
SMG1. This competition reveals a hitherto
Figure 1. Conformational Changes and Hierarchy of Interactions on the SMG1 Scaffolding
Kinase during NMD
1) UPF1 unbound. 2) SMG8 and SMG9 association promote a conformational change and result in inhibi-
tion of SMG1 activity. 3a) UPF1 docks at the head region of SMG1 in proximity of the kinase active site. 3b)
UPF2 can bind to SMG1 in an UPF1-independent manner. 4) Pentameric complex formation requires
binding of UPF1 CH domain to UPF2, resulting in UPF1 activation. Black arrows represent sequential
steps, and the gray arrow represents an unfavorable directionality of the assembly process.
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Previewsunknown complexity in the regulation of
the assembly of SMG1 complexes.
In the future, it will be interesting to
see which of the SMG1/8/9-UPF1/2
complexes is competent to interact with
downstream effectors during NMD. This
will also give insights on how alternative
NMD pathways that have been proposed
to act independently of the EJC, of UPF3
or UPF2, might function at the onset of
NMD. Another interesting question is
how UPF3 binds to the complex andhow this contributes to the activation of
SMG1. Is UPF3 involved in the release of
SMG8 and SMG9? The approach taken
by Melero et al. (2014) will be useful
to answer these questions in the future.
The combination of EM and various
biochemical assays, including crosslink-
ing to stabilize labile interactions, is a
powerful means to obtain structure-
function information from low amounts
of large and dynamic multiprotein assem-
blies operating during NMD.Structure 22, August 5, 2014ACKNOWLEDGMENTS
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